Department of Dentomaxillofacial Radiology, Nanjing Stomatological Hospital, Medical School of Nanjing University, Zhong Yang Road 30, Nanjing City, Jiangsu Province, 210008, People's Republic of China.
Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing University, Zhong Yang Road 30, Nanjing City, Jiangsu Province, 210008, People's Republic of China.
Invest New Drugs. 2021 Aug;39(4):1132-1138. doi: 10.1007/s10637-021-01082-w. Epub 2021 Feb 16.
Due to immune impairment and lymphocyte enrichment of oral squamous cell carcinoma (OSCC), anti-PD-1/PD-L1 therapy is regarded as a potential treatment option. However, tumor heterogeneity, differences in the immune conditions of patients, and the interrelation between tumor cells and stromal cells within the tumor microenvironment (TME) could affect the therapeutic efficacy of immune checkpoint blockades. Therefore, to maximize the benefit of blockade PD-1/PD-L1 axis, to find an efficient predictor (the possible clinical parameters or biological factors) before treatment are of great importance. In this review, we discuss the advantages of anti-PD-1/PD-L1 therapy for OSCC patients and find three respects that are currently available in predicting curative effect. Firstly, OSCC with high PD-L1 expression evaluating by immunohistochemistry (high tumor proportion score (TPS) and combined positive score (CPS)) are considered to be suitable for anti-PD-1/PD-L1 therapy. Secondly, gene-level predictive biomarkers including high metastatic mismatch repair deficiency (dMMR) signature or enrichment of interferon-γ and PD1 signaling pathway is expected to be favorable factors. Besides, PET/CT parameters (SUV, MTV, TLG) are proved to be correlated with PD-L1 expression, and some newly developed immunoPET probes are enlarging the application of PET/CT in predicting therapeutic efficacy of PD-1/PD-L1 inhibitors.
由于口腔鳞状细胞癌（OSCC）存在免疫受损和淋巴细胞富集，抗 PD-1/PD-L1 治疗被认为是一种潜在的治疗选择。然而，肿瘤异质性、患者免疫状况的差异以及肿瘤微环境（TME）中肿瘤细胞与基质细胞之间的相互关系，都可能影响免疫检查点阻断的治疗效果。因此，为了最大限度地发挥 PD-1/PD-L1 轴阻断的疗效，在治疗前找到有效的预测指标（可能的临床参数或生物学因素）非常重要。在这篇综述中，我们讨论了抗 PD-1/PD-L1 治疗 OSCC 患者的优势，并找到了目前可用于预测疗效的三个方面。首先，通过免疫组织化学（高肿瘤比例评分（TPS）和联合阳性评分（CPS））评估的 PD-L1 高表达的 OSCC 被认为适合抗 PD-1/PD-L1 治疗。其次，基因水平的预测生物标志物，包括高转移性错配修复缺陷（dMMR）特征或干扰素-γ和 PD1 信号通路的富集，预计是有利的因素。此外，PET/CT 参数（SUV、MTV、TLG）已被证明与 PD-L1 表达相关，一些新开发的免疫 PET 探针扩大了 PET/CT 在预测 PD-1/PD-L1 抑制剂治疗效果中的应用。
